| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company's novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.
Posted In: CLRB
